AstraZeneca’s Lung Cancer Pill Wins EU Approval
Three months after US regulators gave the treatment the green light, AstraZeneca’s new lung cancer pill, Tagrisso, has won early approval for use in the EU. Tagrisso, also known by its clinical name osimertinib AZD9291, is one of six cancer medicines that AstraZeneca hopes will rebuild its sales after losing patent on older drugs.